PBE Fail-to-Deliver

Invesco Biotechnology & Genome ETF (PBE) operates in the Financial Services sector, specifically the Asset Management industry, with a market capitalization near $298.4M, listed on AMEX, carrying a beta of 0.71 to the broader market. The Invesco Biotechnology & Genome ETF (PBE) seeks to replicate the performance of the Dynamic Biotech & Genome Intellidex Index. public since 2005-06-23.

No records carrying symbol PBE appear in the SEC's published NSCC CNS fails-to-deliver data for settlement dates September 22, 2026 through October 14, 2026.

Most recent fail-to-deliver in our records: September 21, 2026.

Frequently asked PBE fail-to-deliver questions

Has PBE had any fails-to-deliver recently?
No records carrying symbol PBE appear in the SEC's published NSCC CNS fails-to-deliver data for settlement dates September 22, 2026 through October 14, 2026. Most recent fail-to-deliver in our records: September 21, 2026. The SEC publishes the first half of each month at the month's end and the second half around the 15th of the next month, so this check covers settlement dates through October 14, 2026.
What does it mean when PBE is absent from the SEC fails-to-deliver data?
The SEC's files give the aggregate net balance of shares that failed to be delivered in NSCC's Continuous Net Settlement system, by security and settlement date. Since September 16, 2008 a security has a record for every settlement date on which that balance was above zero, and none when it was zero. This check is by symbol, so a fail reported only under a CUSIP or a former symbol is not counted.

Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.

Learn how fails-to-deliver is reported and how to read the data →